Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2010 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

On 11 May 2001, orphan designation (EU/3/01/036) was granted by the European Commission to Pharming N.V., Belgium, for recombinant human C1-inhibitor for the treatment of angioedema caused by C1 inhibitor deficiency.

The sponsorship of this orphan medicinal product was transferred to Pharming Group N.V., The Netherlands, in November 2002.

Key facts

Active substance
Recombinant human C1-inhibitor
Disease / condition
Treatment of angioedema caused by C1 inhibitor deficiency
Date of first decision
EU designation number

Sponsor's contact details

Pharming Group N.V.
Darwinweg 24
2300 AL Leiden
The Netherlands
Tel. +31 71 52 47 400

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating
1 rating